<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01736644</url>
  </required_header>
  <id_info>
    <org_study_id>TD-07709</org_study_id>
    <nct_id>NCT01736644</nct_id>
  </id_info>
  <brief_title>Bipolar Sealer Aquamantys Use in Total Knee Replacement</brief_title>
  <official_title>A Prospective Randomized Control Trial to Compare the Aquamantys System With Standard Electrocautery in Reducing Blood Loss in Primary Total Knee Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Surgical Technologies</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Surgical Technologies</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will compare the clinical outcomes for patients undergoing a total knee&#xD;
      replacement using a bipolar sealer, the Aquamantys® System, as compared to standard&#xD;
      electrocautery. Total blood loss during the hospital stay and knee mobility and discharge&#xD;
      factors will be analyzed.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2012</start_date>
  <completion_date type="Actual">October 27, 2013</completion_date>
  <primary_completion_date type="Actual">October 27, 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood Loss</measure>
    <time_frame>upto to 72 hrs after surgery</time_frame>
    <description>The primary outcome will be total blood loss throughout the hospital stay.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rehabilitation</measure>
    <time_frame>6-weeks</time_frame>
    <description>Discharge criteria evaluated.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">97</enrollment>
  <condition>Osteoarthritis</condition>
  <condition>Arthritis</condition>
  <condition>Surgery</condition>
  <condition>Infection</condition>
  <condition>Inflammation</condition>
  <condition>Disability</condition>
  <condition>Hemorrhage</condition>
  <arm_group>
    <arm_group_label>Electrocautery</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Use of electrocautery in tourniquet and without tourniquet total knee replacement surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bipolar Sealer Aquamantys</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Use of bipolar sealer Aquamantys in tourniquet and tourniquetless total knee replacement surgical procedures.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Electrocautery</intervention_name>
    <description>Use of electrocautery in tourniquet and tourniquetless total knee replacement surgery</description>
    <arm_group_label>Electrocautery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Bipolar sealer Aquamantys</intervention_name>
    <description>Aquamantys use in tourniquet and tourniquetless total knee replacement.</description>
    <arm_group_label>Bipolar Sealer Aquamantys</arm_group_label>
    <other_name>Aquamantys</other_name>
    <other_name>AQM</other_name>
    <other_name>Bipolar sealer</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient is ≥18 years of age&#xD;
&#xD;
          -  Patient has failed conservative therapy of osteoarthritis of the knee and has been&#xD;
             listed to undergo primary TKA&#xD;
&#xD;
          -  Patient is willing and able to provide written informed consent.&#xD;
&#xD;
          -  Pre-assessment Haemoglobin ≥ 11.0g/dl&#xD;
&#xD;
          -  Patient is suitable to receive spinal anaesthesia with no peripheral nerve blocks&#xD;
&#xD;
          -  Patients willing to undergo blood transfusion&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients that are listed for unicondylar or revision TKA&#xD;
&#xD;
          -  Patients who are being converted from a previous high tibial osteotomy and a previous&#xD;
             unicondylar knee arthroplasty&#xD;
&#xD;
          -  Fixed motor deficit thus affecting functional assessment of the knee&#xD;
&#xD;
          -  Patients presenting with a non-osteoarthritis degenerative knee diagnosis&#xD;
&#xD;
          -  Patients presenting with known contralateral knee osteoarthritis requiring&#xD;
             simultaneous bilateral TKA&#xD;
&#xD;
          -  Patients presenting with a history of previous knee infection&#xD;
&#xD;
          -  Patients presenting with a pre-operative knee range of motion &lt; 85°&#xD;
&#xD;
          -  Knee deformity greater than 20 degrees varus or valgus&#xD;
&#xD;
          -  Patients presenting with a history of bleeding disorders and/or are on chronic blood&#xD;
             anticoagulation therapy&#xD;
&#xD;
          -  Patients with significantly impaired renal function (defined by EGFR &gt;30)&#xD;
&#xD;
          -  Patients with allergy or sensitivity to non-steroidal anti-inflammatory drugs,&#xD;
             ropivacaine, ketoprofen or adrenaline&#xD;
&#xD;
          -  Patients presenting with an internal cardiac defibrillator&#xD;
&#xD;
          -  Women who are pregnant&#xD;
&#xD;
          -  Evidence of active (systemic or local) infection at time of surgery&#xD;
&#xD;
          -  Patients who have habitual opioid use&#xD;
&#xD;
          -  Patients who have a psychiatric or mental illness which could impair the consent&#xD;
             process or ability to complete patient-report questionnaires&#xD;
&#xD;
          -  Morbid obesity [BMI &gt; 40]&#xD;
&#xD;
          -  Patients who are unwilling to undergo blood transfusion, if necessary&#xD;
&#xD;
          -  Patients who are receiving any implant used in conjunction with a customised-cutting&#xD;
             block system&#xD;
&#xD;
          -  Any patient who cannot or will not provide written informed consent for participation&#xD;
             in the study&#xD;
&#xD;
          -  Those whose prospects for a recovery to independent mobility would be compromised by&#xD;
             known coexistent, medical problems&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard E Field, Md, PhD, FRCS</last_name>
    <role>Principal Investigator</role>
    <affiliation>SWLEOC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>South West London Elective Orthopaedic Center</name>
      <address>
        <city>Epsom</city>
        <state>Surrey</state>
        <zip>Kt18 7EG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Freeman Hospital</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Marulanda GA, Krebs VE, Bierbaum BE, Goldberg VM, Ries M, Ulrich SD, Seyler TM, Mont MA. Hemostasis using a bipolar sealer in primary unilateral total knee arthroplasty. Am J Orthop (Belle Mead NJ). 2009 Dec;38(12):E179-83.</citation>
    <PMID>20145794</PMID>
  </reference>
  <reference>
    <citation>Marulanda GA, Ragland PS, Seyler TM, Mont MA. Reductions in blood loss with use of a bipolar sealer for hemostasis in primary total knee arthroplasty. Surg Technol Int. 2005;14:281-6.</citation>
    <PMID>16525984</PMID>
  </reference>
  <reference>
    <citation>Pfeiffer M, Bräutigam H, Draws D, Sigg A. A new bipolar blood sealing system embedded in perioperative strategies vs. a conventional regimen for total knee arthroplasty: results of a matched-pair study. Ger Med Sci. 2005 Dec 13;3:Doc10.</citation>
    <PMID>19675727</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>November 20, 2012</study_first_submitted>
  <study_first_submitted_qc>November 26, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 29, 2012</study_first_posted>
  <last_update_submitted>February 25, 2020</last_update_submitted>
  <last_update_submitted_qc>February 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>blood loss</keyword>
  <keyword>bipolar sealer</keyword>
  <keyword>aquamantys</keyword>
  <keyword>total knee replacement</keyword>
  <keyword>primary total knee arthroplasty</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

